国际肿瘤学杂志

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (7): 515-517.doi: 10.3760/cma.j.issn.1673422X.2014.07.010

• 综述 • 上一篇    下一篇

表皮生长因子受体酪氨酸激酶抑制剂的耐药机制

熊杏安, 王梦, 蔡志强   

  1. 434000 荆州，长江大学附属第一医院药剂科
  • 出版日期:2014-08-04 发布日期:2014-08-04
  • 通讯作者: 蔡志强，Email:helloasha@163.com E-mail:helloasha@163.com

The mechanism research of EGFRTKI resistance

 XIONG  Xing-An, WANG  Meng, CAI  Zhi-Qiang   

  1. Departmentof Pharmacy, First Affiliated Hospital of Yangtze University， Jingzhou,434000 China
  • Online:2014-08-04 Published:2014-08-04
  • Contact: Cai Zhiqiang E-mail:helloasha@163.com

PDF

1325

摘要： 表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）在非小细胞肺癌(NSCLC)中的耐药越来越常见，主要包括原发性耐药与继发性耐药，其中原发性耐药主要与EGFR基因突变有关，继发性耐主要与T790M、MET等基因相关。

关键词: 受体, 表皮生长因子, 抗药性, 肿瘤, 酪氨酸激酶抑制剂

Abstract: Epidermal growth factor receptor  tyrosine kinase inhibitor (EGFRTKI) resistance in nonsmall cell lung cancer(NSCLC) has become more and more common, which includes primary and secondary resistance. The primary resistance is mainly related with EGFR gene mutation, and the secondary resistant is mainly related with T790M, MET and other genes.

Key words: Receptor,epidermal growth factor, Drug resistance,neoplasm, Tyrosine kinase inhibitor